FOR THE TREATMENT OF GLAUCOMA AND OCULAR HYPERTENSION
“If approved, OTX-TP may become the first non-invasive, sustained release therapy for the treatment of glaucoma.”
Amar Sawhney, CEO
OTX-TP (travoprost insert) is a preservative-free drug product candidate that is inserted into the canaliculus and is designed to deliver the prostaglandin analog travoprost to the ocular surface for up to 90 days. OTX-TP is designed to deliver a continuous steady release throughout the treatment period. The Company is currently enrolling patients in the first of two planned phase 3 trials with OTX-TP for the treatment of Glaucoma.
Caution: NEW DRUG – OTX-TP is currently undergoing clinical evaluation in the United States and is limited by United States law to investigational use only. This product has not been approved by the FDA as safe or effective.
Glaucoma is a sight-threatening disease caused by elevated intraocular pressure. Over time, this elevated pressure leads to degeneration of cells which make up the optic nerve, slowly decreasing vision. Almost 2.3 million Americans age 40 and older have been diagnosed with the disease,1 with over 30 million glaucoma prescriptions in 2013.2 According to the World Health Organization, it is the second leading cause of blindness worldwide.3 It is a chronic condition which cannot be prevented or reversed, and therefore must be monitored for life.
Compliance is seen as the biggest problem with existing therapies for glaucoma, and more than 50% of patients on topical prostaglandin analogs are not adherent with their therapy within the first six months of treatment.4
Prostaglandin analog intracanalicular inserts may help manage the issues of non-compliance by vastly reducing dosing frequency.